Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 670 across all filing types
Latest filing 2022-01-04 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
实际控制人彭志恩关于奥锐特股票交易异常波动征询函的回函
Regulatory Filings Classification · 100% confidence The document is a response letter from the actual controller of the company regarding an inquiry about abnormal stock trading fluctuations. It explicitly states that no undisclosed major events affecting stock price exist. The content is a regulatory response to a stock exchange inquiry, not a financial report or announcement of a meeting or vote. It is short (321 characters) and serves as a regulatory compliance communication. Therefore, it fits best under Regulatory Filings (RNS).
2022-01-04 Chinese
控股股东浙江桐本投资有限公司关于奥锐特股票交易异常波动征询函的回函
Regulatory Filings Classification · 95% confidence The document is a response letter to an inquiry about abnormal stock trading fluctuations. It states that the company has no undisclosed major events affecting stock price volatility. The content is a regulatory communication addressing stock trading concerns, not a financial report, announcement of voting results, or management change. It is a regulatory filing related to stock trading inquiries and disclosures, fitting best under Regulatory Filings (RNS). The document is short and formal, confirming no material undisclosed information, which aligns with regulatory compliance communications.
2022-01-04 Chinese
奥锐特药业股份有限公司关于公司股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement by the company 奥锐特药业股份有限公司 regarding abnormal stock price fluctuations over specific trading days. It includes details about the investigation into the cause of the price movements, confirmation of no undisclosed material information, and a risk warning to investors. The document is relatively short (1353 characters) and focuses on stock trading irregularities rather than financial results, management changes, or other report types. It does not contain financial statements or detailed financial data. This type of announcement fits the category of a Regulatory Filing (RNS), as it is a compliance disclosure related to stock price movements and regulatory requirements under the Shanghai Stock Exchange rules, and does not fit into more specific categories like Earnings Release or Capital/Financing Update.
2022-01-04 Chinese
控股股东浙江桐本投资有限公司关于奥锐特股票交易异常波动征询函的回函
Regulatory Filings Classification · 95% confidence The document is a response letter to an inquiry about abnormal stock trading fluctuations. It explicitly states that there are no undisclosed major events affecting the stock price. The content is a regulatory communication addressing stock trading concerns, not a financial report, management change, or other specific filings. The document is short (311 characters) and serves as a formal reply to a regulatory inquiry, fitting best under general regulatory announcements.
2021-12-03 Chinese
实际控制人彭志恩关于奥锐特股票交易异常波动征询函的回函
Regulatory Filings Classification · 95% confidence The document is a response letter from the actual controller of the company regarding an inquiry about abnormal stock trading fluctuations. It states that there are no undisclosed major events affecting stock price volatility. The document is short (323 characters) and is a regulatory response rather than a financial report or announcement of a meeting or vote. It does not contain financial data, management changes, or voting results. It fits best under Regulatory Filings (RNS) as a compliance-related disclosure.
2021-12-03 Chinese
奥锐特药业股份有限公司股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement by 奥锐特药业股份有限公司. It details the stock price drop over three consecutive trading days exceeding 20%, confirms no undisclosed major information, and clarifies that no significant events or insider trading occurred that could explain the price movement. The document references compliance with Shanghai Stock Exchange trading rules and provides a risk warning to investors. It does not contain financial statements, earnings data, or management discussion, nor is it a report or presentation. It is a regulatory announcement about stock price abnormality and related disclosures, fitting the category of Regulatory Filings (RNS). The document length is short (1339 characters), and it is not an announcement of a report but a standalone disclosure.
2021-12-03 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.